ARTAN Bio(VitaRNA) and Syenex just announced a strategic collaboration that could significantly speed up the development of ARTAN-102, a pioneering gene therapy designed to reverse epigenetic changes associated with aging. This partnership brings together ARTAN's innovative codon suppressor platform with Syenex's VivoCell delivery technology.
The Power of Precision Delivery
The collaboration centers on a critical challenge in gene therapy: getting the treatment to the right places in the body. Syenex's VivoCell Platform provides the precision in vivo delivery capabilities that ARTAN needs to move their therapy from laboratory proof-of-concept to IND-enabling studies - the crucial step before human trials can begin.
"Precise, efficient delivery is critical to maximizing the potential of ARTAN-102," explained Dr. Michael Torres, Co-Founder and Chief Scientific Officer of ARTAN Bio. "Syenex's track record in delivery vehicle innovation and manufacturing scale makes them a natural partner as we progress toward IND-enabling studies."
What the Partnership Includes
The collaboration has three main components:
- Rapid Prototyping: ARTAN gains full access to the VivoCell Platform, including extensive libraries of precision delivery components. Syenex will provide pre-clinical scale prototyping and production support, allowing ARTAN to quickly test and refine delivery approaches.
- Manufacturing Scale-Up: Once optimal prototypes are developed, they'll be transferred to Syenex's CDMO (Contract Development and Manufacturing Organization) partners for GMP-grade production - the pharmaceutical quality standard required for clinical trials.
- Flexible Licensing: The agreement includes a non-exclusive program license option for the clinical delivery vehicle composition, giving ARTAN strategic flexibility as they move forward.
About ARTAN-102 and VitaRNA
ARTAN Bio, also known as VitaRNA, is developing first-in-class therapeutics designed to restore full-length, functional proteins that become disrupted during aging and age-related disease. Their lead candidate, ARTAN-102, uses a novel codon suppressor approach to address mutations that accumulate as we age, particularly targeting proteins crucial for tumor suppression, DNA repair, and neurological function.
The VitaRNA project recently released impressive first in vivo data showing ARTAN-102 is safe and reaches multiple tissues in mice. The 14-day study found the therapy successfully reached the liver (350-fold increase), heart (32-fold), lungs (20-fold), brain (4-fold), kidneys (10-fold), and pancreas (12-fold) - all without adverse effects, changes in body weight, or blood cell count alterations.
Jay Rosanelli, CEO of Syenex, emphasized the potential impact: "ARTAN Bio has generated strong preclinical data on the therapeutic potential of their lead drug candidate, ARTAN-102. By combining their codon suppressor platform with our VivoCell Platform, we aim to shorten development timelines and unlock treatment options for aging and age-related disease."
